HC Wainwright Reaffirms Buy Rating for XOMA (NASDAQ:XOMA)

HC Wainwright reaffirmed their buy rating on shares of XOMA (NASDAQ:XOMA) in a report published on Friday morning, Stock Target Advisor reports. The brokerage currently has a $30.00 target price on the biotechnology company’s stock.

A number of other equities analysts also recently weighed in on XOMA. ValuEngine raised XOMA from a sell rating to a hold rating in a research report on Tuesday, December 3rd. Zacks Investment Research raised XOMA from a hold rating to a buy rating and set a $24.00 price objective for the company in a research report on Saturday, November 9th. Finally, TheStreet raised XOMA from a d+ rating to a c rating in a research report on Tuesday, November 12th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $26.33.

Shares of XOMA opened at $25.49 on Friday. The firm has a 50-day moving average of $22.25 and a 200-day moving average of $18.85. XOMA has a one year low of $11.02 and a one year high of $26.90. The company has a market cap of $212.77 million, a PE ratio of -16.03 and a beta of 1.28. The company has a debt-to-equity ratio of 1.31, a current ratio of 4.37 and a quick ratio of 4.37.

XOMA (NASDAQ:XOMA) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.68. XOMA had a negative net margin of 10.19% and a negative return on equity of 8.93%. The company had revenue of $8.86 million for the quarter. Analysts expect that XOMA will post -0.22 earnings per share for the current year.

In other news, CEO James R. Neal sold 4,348 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $22.00, for a total value of $95,656.00. Following the transaction, the chief executive officer now owns 22,017 shares of the company’s stock, valued at $484,374. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Thomas M. Burns sold 3,829 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $21.96, for a total value of $84,084.84. Following the transaction, the chief financial officer now owns 10,384 shares in the company, valued at approximately $228,032.64. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 17,459 shares of company stock valued at $374,142. Company insiders own 9.89% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Athanor Capital LP acquired a new position in XOMA in the 2nd quarter valued at $149,000. Squarepoint Ops LLC bought a new stake in shares of XOMA in the third quarter valued at about $244,000. Morgan Stanley boosted its position in shares of XOMA by 2,151.6% in the second quarter. Morgan Stanley now owns 23,889 shares of the biotechnology company’s stock valued at $355,000 after acquiring an additional 22,828 shares during the period. Marshall Wace LLP acquired a new position in shares of XOMA in the second quarter valued at about $434,000. Finally, Paloma Partners Management Co acquired a new position in shares of XOMA in the second quarter valued at about $510,000. 37.20% of the stock is owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

See Also: Buyback For Investors Defined

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.